Recent studies have found that 22 genes can be used as targets for BC immunotherapy7, and long non-coding RNA T-cell leukaemia/lymphoma 6 (TCL6) may play a protective role in BC through immune infiltration8. This evidence concerns the gene TCL6 and breast cancer.